FUJIFILM Corporation Announces Results from Phase II Clinical Trial of "T-817MA" in Patients with Alzheimer's Disease in the United States
FUJIFILM Corporation (TOKYO: 4901) (President: Kenji Sukeno) announced that the company’s Alzheimer’s Disease drug “T-817MA,” did not meet its primary study endpoints of cognition or global clinical function in its Phase II clinical trial conducted in the United States on patients with mild to moderate Alzheimer’s Disease (AD). There were no significant differences in secondary outcomes. In exploratory analyses, change of the cerebrospinal fluid (CSF) biomarker phospho-tau (p-Tau) benefited from the higher dose treatment while hippocampal*1 volumes decreased less in the lower doses group with statistical significance. Post hoc analyses also suggested T-817MA treatment with shorter duration of illness and symptoms was associated with better cognitive outcomes with statistical significance. Fujifilm will review the results of the Phase II clinical trial with regulatory authorities including FDA (U.S. Food and Drug Administration) and will take necessary steps toward further development including Phase III clinical trial of this compound.
A pre-clinical research, led by Dr. Rudolph Tanzi, Joseph P. and Rose F.
Kennedy Professor of Neurology at Harvard Medical School, and Vice-Chair
of Neurology at Massachusetts General Hospital, revealed that T-817MA
acts on microglia*2 that have a risk gene for AD and promotes
the clearance of amyloid-β (Aβ).
These results suggest that T-817MA may act on p-Tau and Aβ, major causal substances in AD.
AD’s main symptoms are abnormalities in cognitive functions, including
memory. It is believed that abnormality of neurological functions in AD
manifests as a result of Aβ protein deposits (senile plaques) in the
brain. The progression of the disease has strong association with the
formation of abnormal assemblies caused by hyperphosphorylation and
fibrillization of tau proteins, found in the axons of nerve cells
(neurofibrillary tangle), synapse*3 loss and atrophy of the
brain including hippocampus.
The number of people suffering from dementia is estimated to be 44 million around the world. The number is projected to increase to 76 million by 2030 with the aging of the world population. Over half of these dementia cases suffer from AD, and the trend is set to continue.
AD drugs currently available on the market include acetylcholinesterase inhibitors, such as donepezil hydrochloride. As these drugs address the deficit in neurotransmission to give temporary improvement to the patients' symptoms, there is an unmet need for a new class of therapies to treat AD.
T-817MA is an AD drug discovered by the Fujifilm Group company, Toyama Chemical. It has potent neuroprotective effect and promotes neurite outgrowth through the activation of sigma receptors*4, demonstrating strong efficacy in animal models. Fujifilm is committed to further accelerating the development of T-817MA under possible partnerships, and contributing to resolving social challenges through the delivery of innovative pharmaceutical products.
|*1||Hippocampus is a region of the cerebrum, associated with memory. AD causes neuronal loss, which results in hippocampal atrophy.|
|*2||Microglia are a type of glia cells, which are component of the central nervous system. Microglia provide immune defense in the brain, while also being involved in repairing abnormal neural cells, and eliminating the aggregated Aβ. At the same time, excessively activated microglia are known to play a role in neuro-degeneration in the central nervous system.|
|*3||Synapse is a structure connecting neurons, allowing them to pass electrical signals to convey information between them.|
|*4||Sigma receptors are protein that exists on the membrane of endoplasmic reticulum in cells, and have the function of mitigating neuro-degeneration in the central nervous system.|
For enquiries on information in this media release, contact:
Kana Matsumoto, +81 3-6271-2000
Corporate Communications Division
Pharmaceutical Products Division
TEL +81 3-6271-2171
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pandora to Acquire Leading Digital Audio Ad Tech Firm AdsWizz21.3.2018 13:00 | Pressemelding
Pandora (NYSE: P), the largest music streaming service in the U.S., today announced it will acquire AdsWizz, the global leader in digital audio ad technology. The addition of AdsWizz will upgrade Pandora’s ad tech capabilities, provide its advertisers with greater audience reach, and expand the company’s revenue opportunities. AdsWizz is one of the few ad tech firms that is completely dedicated to digital audio, serving some of the largest players in the industry. With digital audio advertising growing 42% year-over-year, according to the IAB, the combined offering of Pandora and AdsWizz will capitalize on this trend, while making it easier for publishers to monetize their inventory, and for advertisers to buy and measure their campaigns. “Since I joined Pandora six months ago, I have highlighted ad tech as a key area of investment for us. Today we took an important step to advance that priority and accelerate our product roadmap,” said Roger Lynch, CEO of Pandora. “With our scale in a
Fintech Entrepreneur and myPOS Founder Christo Georgiev Reveals Plans to Set Up a Chain of myPOS Stores across Europe21.3.2018 12:51 | Pressemelding
Founder of myPOS, Christo Georgiev announces plans to open myPOS flagship stores across Europe in an effort to bring the service closer to its customers. Designed for small and mid-sized businesses, myPOS offers affordable payment acceptance tools, winning the trust of over 40,000 enterprises across the EEA & Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180321005596/en/ An interior view of the myPOS London Store (Photo: Business Wire) Until now, the operational framework of myPOS included a network of promoters in almost every European country and an online store, owned and operated by myPOS. The next logical step was to sell through physical stores. On 8th February 2018, myPOS opened doors to its first flagship store, located on 36 Knightsbridge, London and marked the beginning of a new era for myPOS. Soon after, plans were revealed for other openings in Europe with another location coming up on 5th April 201
AI Expo Europe: The leading Artificial Intelligence Event to Arrive in the European Capital of Innovation, Amsterdam21.3.2018 12:47 | Pressemelding
The AI Expo Europe is set to arrive in the hub of AI innovation, Amsterdam, The Netherlands, this Summer (27-28th June) with an aim of ‘delivering AI for a smarter future.’ The well-connected Dutch capital is known for its unique, rich culture and canal-side views and was even awarded the European Capital of Innovation in 2016 by the European Commission. The city’s AI scene is thriving with the arrival of a world-class artificial intelligence hub by early 2021 and venture capitalist investment. The AI hub will be created in collaboration with the University of Amsterdam (UvA) and the City of Amsterdam at the Amsterdam Science Park, a place where education, research and entrepreneurship will come together as one. Geert ten Dam, president of the UvA’s Executive Board stated that: “Amsterdam is widely recognised both in the Netherlands and abroad for its leading scientific expertise in the area of AI…” This press release features multimedia. View the full release here: https://www.busines
Philip Morris International Shifts Entire Capacity of Its Cigarette Factory in Greece to Smoke-Free Products21.3.2018 12:31 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE: PM) announced today that the factory of its Greek affiliate (Papastratos) in Aspropyrgos, has ceased cigarette production and is now exclusively producing HEETS, the tobacco units used with IQOS, the company’s most advanced smoke-free product. This first full conversion of a cigarette factory is a landmark step in our vision of a smoke-free future where people who smoke switch from the most harmful form of nicotine consumption – cigarettes – to scientifically substantiated smoke-free alternatives. The EUR 300 million investment included the construction of three new buildings and the replacement of cigarette production lines with high-tech facilities capable of producing 10,000 smoke-free tobacco units per minute. The conversion of the factory started in August 2017. The facility is expected to be fully operational by the end of 2018 and will create 400 new jobs. André Calantzopoulos, PMI’s Chief Executive Officer said: “This is a historic
GSMA Advances a Comprehensive Agenda on Digital Inclusion for Women Ahead of G20 Summit21.3.2018 12:00 | Pressemelding
The GSMA is supporting the sixty-second meeting of the Commission on the Status of Women (CSW62) taking place at the United Nations Headquarters in New York this month1 as part of its commitment to the Sustainable Developments Goals (SDGs), particularly SDG 5 (Gender Equality). The GSMA’s role at the event reflects its status as Topic Chair of the Digital Inclusion theme within the W20 (Women 20) group2, which will advise the G20 member states on issues around gender equality and the economic empowerment of women. At CSW62, the GSMA and its partners will be convening parallel events across a range of topics in this area, bringing together companies in the mobile ecosystem, governments, UN agencies and NGOs. “Developing forward-looking policies that promote digital inclusion for women is vital to achieving gender equality, serving to empower women in all corners of the world as well as providing an effective catalyst for economic growth,” said Mats Granryd, Director General of the GSMA.
fundinfo Launches New Fund News Service in Cooperation with UBS21.3.2018 08:00 | Pressemelding
To provide investors with up-to-date information and views from the fund managers with which they are invested fundinfo has launched a new service, in cooperation with UBS Global Wealth Management, that enables fund providers to publish fund-specific news in an automated and systematic way. The new service, known as News Dissemination, allows fund managers to provide their insights on the impact of recent market or political event – information not typically available in most fund documents. It is fully integrated into UBS's client-facing applications such as UBS eBanking, UBS Quotes, and Wealth Management Online (WMO). The service can also be integrated by other distributors. The easy-to-manage service, allows fund managers to create, edit and archive their news via a web-based fundinfo content management system, giving them complete control at all times. "This is a game changer. It's the first time fund providers have the opportunity to deliver ad-hoc and near real-time insights on t